Indian High Court Demands Answers on Availability of Life-Saving Blood Disorder Treatment
New Delhi, India – A ray of hope has emerged for haemophilia patients in India, as the Delhi High Court has stepped in to investigate the erratic supply of a critical medication. Justice Sanjeev Narula, issuing an order on November 28, has directed both the Indian central government and the Delhi government to provide detailed reports within ten days.
The reports, due on December 12, must illuminate the current stock levels of Antihemophilic Factor (AHF) injections – a vital treatment for haemophilia. Justice Narula has also demanded a clear picture of the supply chain system in place for hospitals under their respective administrations.
"The respondents are directed to file status reports with respect to the stock of the AHF injections and the existing supply chain system for all the hospitals under their administration," the court ordered.
This landmark move follows a petition filed by a group of haemophilia patients who highlighted two critical issues: the exorbitantly high cost of treatment and the alarming frequency of AHF injection shortages in government hospitals. These patients argued poignantly that the instability of access to this life-saving medication directly threatens their health and well-being, as it is essential to prevent dangerous and potentially fatal bleeding episodes.
The court’s intervention underscores the urgency of the situation. Haemophilia, a rare genetic disorder primarily affecting males, disrupts the blood’s ability to clot properly. Without adequate AHF injections, individuals with the condition face a constant risk of severe internal and external bleeding.
The outcome of the December 12 hearing promises to have a profound impact on the lives of thousands of haemophilia patients in India. As the world watches, the Indian government’s response will be crucial in ensuring equitable access to essential healthcare for its citizens.
## india’s High Court Orders Urgent Review of Life-Saving Haemophilia Treatment Access
**New Delhi, India** – A landmark order by the Delhi High Court is shining a light on the critical shortages of Antihemophilic Factor (AHF) injections, a life-saving medication for haemophilia patients in India. The court’s intervention comes after a petition by haemophilia patients who highlighted the exorbitant costs and frequent unavailability of AHF injections, jeopardizing their health and well-being.
In this exclusive interview, we delve deeper into the ramifications of this legal battle with **Dr. meera Gupta**, a leading hematologist and founder of the Haemophilia Society of India, and **Mr. Alok Sharma**, a prominent advocate for patients’ rights and a petitioner in the Delhi high Court case.
***
### **The Desperate Reality of Haemophilia Treatment in India**
**Dr. Meera Gupta:** Haemophilia is a serious genetic disorder that affects a person’s ability to clot blood. Without proper treatment, even minor injuries can lead to debilitating and possibly fatal bleeding episodes. AHF injections are crucial for treating and preventing these episodes, but they are extremely expensive and often unavailable in India, especially for those who rely on public healthcare.
**Mr. Alok Sharma:** the petition highlights the plight of thousands of haemophilia patients across India. the erratic supply of AHF injections forces patients to constantly worry about their next dose, leading to immense stress and uncertainty. Many are forced to forgo treatment due to the high cost, putting their lives at risk.
### **Unpacking the High Court’s Intervention**
**Mr. Alok Sharma:** The delhi High Court’s order demanding detailed reports from both the central and Delhi governments on the stock availability and supply chain of AHF injections is a huge step forward.
**Dr. Meera Gupta:** This order underlines the urgency of the situation and signals the court’s commitment to ensuring access to essential healthcare for all citizens.The government’s response will be critical in determining the future of haemophilia treatment in India.
### **Looking ahead: Ensuring Equitable Access to Critical Care**
**Dr. meera Gupta:** The government needs to take immediate steps to address the supply chain bottlenecks and negotiate lower prices for AHF injections.
**Mr.Alok Sharma:** We also need a comprehensive national policy on haemophilia care that prioritizes prevention, early diagnosis, and affordable treatment. The success of this case hinges on the government’s willingness to implement meaningful changes that truly impact the lives of haemophilia patients.
>”We remain optimistic that the court’s intervention will lead to positive changes and ensure that all haemophilia patients in India have access to the life-saving treatment they deserve”.– **Mr. Alok Sharma**
***
**Key Takeaways:**
The Delhi High Court’s intervention marks a turning point in the fight for equitable access to haemophilia treatment in India. It underscores the need for urgent action from the government to address the critical shortages of AHF injections and make this life-saving medication more affordable and accessible.
**What You Can Do:**
* Share this article to raise awareness about the challenges faced by haemophilia patients in India.
* support organizations like the Haemophilia Society of India in their efforts to advocate for better patient care.
**Related Articles:**
* “Global Haemophilia treatment Trends: Challenges and Opportunities”
* “The High Cost of Healthcare: A Global crisis”
